{"id":45287,"date":"2025-10-30T16:59:26","date_gmt":"2025-10-30T08:59:26","guid":{"rendered":"https:\/\/flcube.com\/?p=45287"},"modified":"2025-10-30T16:59:27","modified_gmt":"2025-10-30T08:59:27","slug":"lepu-biopharma-secures-conditional-nmpa-approval-for-becotatug-vedotin-mgr003-in-recurrent-nasopharyngeal-carcinoma","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45287","title":{"rendered":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma"},"content":{"rendered":"\n<p><strong>Lepu Biopharma Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2157:HKG\">HKG: 2157<\/a>) today announced that its antibody\u2011drug conjugate (ADC) <strong>Becotatug\u202fVedotin (MGR003)<\/strong> has received conditional approval from the <strong>National Medical Products Administration (NMPA)<\/strong> of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-product-highlights\"><strong>Product Highlights<\/strong><\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Targeted Mechanism<\/strong> \u2013 MGR003 couples an EGFR\u2011specific monoclonal antibody to the microtubule inhibitor <strong>MMAE<\/strong> via a vc linker.<\/li>\n\n\n\n<li><strong>High\u2011Affinity Binding<\/strong> \u2013 The ADC binds EGFR on tumor cells with nanomolar affinity, is efficiently internalized by endocytosis, and releases MMAE intracellularly to trigger apoptosis.<\/li>\n\n\n\n<li><strong>Clinical Rationale<\/strong> \u2013 Designed for a population with limited options, the therapy offers a novel modality that exploits EGFR over\u2011expression common to nasopharyngeal carcinoma.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\"><strong>Regulatory Milestone<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Conditional Approval<\/strong> \u2013 The NMPA approval is contingent upon the completion of post\u2011marketing surveillance and additional confirmatory studies.<\/li>\n\n\n\n<li><strong>Market Impact<\/strong> \u2013 This approval positions Lepu\u202fBiopharma as a leading ADC developer in the Chinese oncology market and expands access to a first\u2011in\u2011class therapy for a high\u2011need patient group.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003)&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45288,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,1207,3609,15],"class_list":["post-45287","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-hkg-2157","tag-lepu-biopharma","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003) has received conditional approval from the National Medical Products Administration (NMPA) of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45287\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma\" \/>\n<meta property=\"og:description\" content=\"Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003) has received conditional approval from the National Medical Products Administration (NMPA) of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45287\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-30T08:59:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-30T08:59:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma\",\"datePublished\":\"2025-10-30T08:59:26+00:00\",\"dateModified\":\"2025-10-30T08:59:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"HKG: 2157\",\"Lepu Biopharma\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45287#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45287\",\"name\":\"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008.webp\",\"datePublished\":\"2025-10-30T08:59:26+00:00\",\"dateModified\":\"2025-10-30T08:59:27+00:00\",\"description\":\"Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003) has received conditional approval from the National Medical Products Administration (NMPA) of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\\\/PD\u2011L1 inhibitor therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45287\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3008.webp\",\"width\":1080,\"height\":608,\"caption\":\"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45287#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry","description":"Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003) has received conditional approval from the National Medical Products Administration (NMPA) of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45287","og_locale":"en_US","og_type":"article","og_title":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma","og_description":"Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003) has received conditional approval from the National Medical Products Administration (NMPA) of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.","og_url":"https:\/\/flcube.com\/?p=45287","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-30T08:59:26+00:00","article_modified_time":"2025-10-30T08:59:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45287#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45287"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma","datePublished":"2025-10-30T08:59:26+00:00","dateModified":"2025-10-30T08:59:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45287"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45287#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp","keywords":["ADC \/ XDC","Cancer","HKG: 2157","Lepu Biopharma","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45287#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45287","url":"https:\/\/flcube.com\/?p=45287","name":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45287#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45287#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp","datePublished":"2025-10-30T08:59:26+00:00","dateModified":"2025-10-30T08:59:27+00:00","description":"Lepu Biopharma Co., Ltd. (HKG: 2157) today announced that its antibody\u2011drug conjugate (ADC) Becotatug\u202fVedotin (MGR003) has received conditional approval from the National Medical Products Administration (NMPA) of China. The drug is cleared for adult patients with recurrent or metastatic nasopharyngeal carcinoma who have progressed after at least two lines of systemic chemotherapy and PD\u20111\/PD\u2011L1 inhibitor therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45287#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45287"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45287#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp","width":1080,"height":608,"caption":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45287#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lepu\u202fBiopharma Secures Conditional NMPA Approval for Becotatug\u202fVedotin (MGR003) in Recurrent Nasopharyngeal Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3008.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45287"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45287\/revisions"}],"predecessor-version":[{"id":45289,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45287\/revisions\/45289"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45288"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45287"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45287"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}